Mr. Grote’s experience spans over 40 years in the pharmaceutical industry. He has developed and led successful sales and account management teams and brings extensive knowledge pertaining to the payer, distribution, and reimbursement landscape for both retail and specialty products. Mr. Grote joined Halozyme in October of 2022 as VP, Market Access, Trade and Reimbursement before his promotion to Chief Commercial Officer in May of 2023.
Prior to joining Halozyme, Mr. Grote built Novo Nordisk’s account management, strategy and contracting team to support the company’s biopharmaceutical portfolio. In his role as Vice President, Market Access, Biopharm, he created and executed strategies to enable Norditropin® to become the market share leader in the growth hormone category. He was awarded Novo Nordisk’s coveted International Operations Manager of the Year in 2016 in recognition of his accomplishments.
Mr. Grote was also an initial developer of HEMA Biologics, a start-up joint venture between US WorldMeds and LFB of France. As Vice President, Commercial Operations, he helped successfully launch their first product, Sevenfact® in 2021. He started his career in pharmaceutical sales with the Upjohn Company with progressive responsibilities in sales, sales management, account management and management of account management teams through its lineage of companies, including Pharmacia & Upjohn, Pharmacia, and Pfizer.
Mr. Grote received his B.S. in Zoology with a minor in Chemistry from the Ohio State University.